Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine
- PMID: 9314346
- DOI: 10.1016/s0091-6749(97)70247-1
Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine
Abstract
Background: In some previous studies, the antihistamine cetirizine has inhibited both developing (at 6 hours) and established (at 24 hours) gross late-phase skin reactions (LPR) to pollen antigens, possibly relevant to clinical drug effects. However, the effects of cetirizine at the histologic level require further definition.
Objective: To characterize cetirizine effects on gross and histologic inflammatory events from 20 minutes to 24 hours after intradermal antigen challenge in sensitive patients.
Methods: Gross and histologic responses to intradermal pollen antigen, codeine, histamine, and buffer diluent were assessed during randomized 7-day treatments with cetirizine and placebo. Accumulated neutrophils, eosinophils, activated (EG2+) eosinophils, and T lymphocytes were quantitated. The degrees of extracellular deposition of lactoferrin from neutrophils and eosinophilic cationic protein (ECP) from eosinophils were also assessed.
Results: During placebo treatment, wheal-and-flare responses were significantly greater to antigen at 20 minutes (p < 0.01) and induration at 6 hours (p < 0.01) at antigen challenge sites than at buffer diluent sites. During cetirizine treatment, these wheal-and-flare responses to antigen were inhibited significantly (p < 0.01) but gross LPRs were not affected. During placebo treatment, significantly more cells per high-power field were found in antigen sites than in buffer sites of neutrophils at 20 minutes (p < 0.01) and 24 hours; than in eosinophils at 20 minutes, 6 hours, and 24 hours (p < 0.01 for each); than in EG2+ cells at 20 minutes (p = 0.004), 6 hours (p = 0.001), and 24 hours (p = 0.02); and at T lymphocyte sites at 24 hours (p = 0.001). Extracellular deposition of lactoferrin and ECP was significantly greater at antigen sites than at buffer sites at 6 and 24 hours. Cetirizine treatment had no significant effect on these responses.
Conclusion: Neutrophils, eosinophils, and T lymphocytes were persistently more common at antigen sites than at buffer sites through 24 hours. Many of these neutrophils and eosinophils were activated, releasing more lactoferrin and ECP into the extracellular dermis for at least 24 hours after antigen challenge. Cetirizine inhibited gross immediate responses to antigen, but not the gross LPR nor the cellular inflammatory responses seen in such LPR sites.
Similar articles
-
Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: effects of cetirizine.J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):806-11. doi: 10.1016/s0091-6749(97)80015-2. J Allergy Clin Immunol. 1997. PMID: 9215249 Clinical Trial.
-
Sequential patterns of inflammatory events during developing and expressed skin late-phase reactions.J Allergy Clin Immunol. 2000 Apr;105(4):776-81. doi: 10.1067/mai.2000.105223. J Allergy Clin Immunol. 2000. PMID: 10756229
-
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.Clin Exp Allergy. 2001 Sep;31(9):1378-84. doi: 10.1046/j.1365-2222.2001.01139.x. Clin Exp Allergy. 2001. PMID: 11591187 Clinical Trial.
-
The involvement of eosinophils in the patch test reaction to aeroallergens in atopic dermatitis: its relevance for the pathogenesis of atopic dermatitis.Clin Exp Allergy. 1993 Feb;23(2):97-109. doi: 10.1111/j.1365-2222.1993.tb00304.x. Clin Exp Allergy. 1993. PMID: 8448687 Review.
-
Use of cetirizine to investigate non-H1 effects of second-generation antihistamines.Ann Allergy. 1992 Feb;68(2):190-6. Ann Allergy. 1992. PMID: 1346737 Review.
Cited by
-
Role of histamine and platelet-activating factor in allergic rhinitis.J Physiol Biochem. 2004 Jun;60(2):101-11. doi: 10.1007/BF03168446. J Physiol Biochem. 2004. PMID: 15457928 Review.
-
New insights into the second generation antihistamines.Drugs. 2001;61(2):207-36. doi: 10.2165/00003495-200161020-00006. Drugs. 2001. PMID: 11270939 Review.
-
Second-generation antihistamines: actions and efficacy in the management of allergic disorders.Drugs. 2005;65(3):341-84. doi: 10.2165/00003495-200565030-00004. Drugs. 2005. PMID: 15669879 Review.
-
MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway.J Invest Dermatol. 2021 May;141(5):1286-1296.e4. doi: 10.1016/j.jid.2020.09.017. Epub 2020 Oct 13. J Invest Dermatol. 2021. PMID: 33058860 Free PMC article.
-
Comparison of inflammatory events during developing immunoglobulin E-mediated late-phase reactions and delayed-hypersensitivity reactions.Clin Diagn Lab Immunol. 1998 Jul;5(4):574-7. doi: 10.1128/CDLI.5.4.574-577.1998. Clin Diagn Lab Immunol. 1998. PMID: 9665969 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources